格隆汇2月11日丨皓文控股(08019.HK)公告，于2026年2月11日，公司与澄迈钧立橡胶有限公司("澄迈钧 立")订立一项不具法律约束力的谅解备忘录。 根据谅解备忘录，公司及澄迈钧立将开展战略性合作，以发展及拓展澄迈钧立的业务(尤以天然橡胶及 相关农业领域为重)。公司与澄迈钧立将探索在农业及相关产业应用生物科技、智能技术及绿色科技， 致力于构建数字化平台，推动专利成果的复制与商业化，并透过香港实现海外扩张。 董事努力探索新的机遇，以提升集团的业绩。该合作将使集团多元化业务，并拓宽收入来源。董事对澄 迈钧立业务的长远前景持乐观态度，并认为潜在合作符合集团及公司股东的整体利益。 ...

董事努力探索新的机遇，以提升本集团的业绩。该合作将使本集团多元化业务，并拓宽收入来源。董事 对澄迈钧立业务的长远前景持乐观态度，并认为潜在合作符合本集团及本公司股东的整体利益。 根据谅解备忘录，本公司及澄迈钧立将开展战略性合作，以发展及拓展澄迈钧立的业务(尤以天然橡胶 及相关农业领域为重)。本公司与澄迈钧立将探索在农业及相关产业应用生物科技、智能技术及绿色科 技，致力于构建数字化平台，推动专利成果的复製与商业化，并透过香港实现海外扩张。 皓文控股(08019)发布公告，于2026年2月11日，本公司与澄迈钧立橡胶有限公司(澄迈钧立)订立一项不 具法律约束力的谅解备忘录(谅解备忘录)。 ...

Core Viewpoint - The final ruling on anti-dumping and countervailing duties ("double reverse") against Chinese erythritol products has been announced, with Tsinghua Biotech facing a maximum combined tax rate of 93.58%, significantly impacting its market competitiveness in the U.S. [2][3] Group 1: Tax Rates and Impact - Tsinghua Biotech's final anti-subsidy rate is 8.63%, and the anti-dumping rate is 84.95%, leading to a total tax rate of 93.58% [2][3] - The company did not qualify for separate rate status, resulting in a nationwide unified tax rate of 184.26% for other producers/exporters without separate rate qualifications [3] - The high tax rates are expected to weaken Tsinghua Biotech's cost competitiveness in the U.S. market, leading to potential order reductions and market share loss [3] Group 2: Market Demand and Supply Dynamics - The U.S. is projected to have a per capita sugar and sweetener consumption of approximately 121 pounds (about 55 kg) in 2025, with erythritol being a popular choice due to its natural and zero-calorie properties [5] - Global demand for erythritol is expected to reach 238,000 tons in 2024, with a compound annual growth rate (CAGR) of 22% from 2020 to 2024, indicating strong market demand [5] - The global erythritol market is forecasted to reach $2.63 billion by 2030, with a growth rate of 21.0% during the 2024-2030 period [5] Group 3: Industry Competition and Challenges - The introduction of new production capacities in 2022 has led to an imbalance in the erythritol market, resulting in increased competition and a risk of low-quality products displacing higher-quality ones [6] - Analysts note that erythritol is not a high-barrier product, and ongoing innovations may highlight its limitations [7] Group 4: Strategic Alternatives - Tsinghua Biotech can potentially circumvent the high tariffs by altering product forms, such as selling processed erythritol products directly to consumers [8] - The company is exploring third-party channels and overseas production to maintain market access in the U.S. [8] - Tsinghua Biotech is also developing alternatives like allulose, which is gaining global recognition and is expected to expand its market significantly [9]

Core Insights - Hong Kong's capital market showed remarkable performance in 2025, with total fundraising reaching $103 billion, a year-on-year increase of 164% [1][3] - The initial public offering (IPO) fundraising amounted to $37.4 billion, up 231% year-on-year, while post-listing refinancing reached $66 billion, a 136% increase [1][3] Group 1: Market Performance - Hong Kong regained its position as the global leader in new stock fundraising by the end of 2025, with 119 new listings raising a total of $37.4 billion, surpassing the total from the previous three years [3] - The average daily trading volume in the secondary market increased by 89.5% year-on-year, indicating high trading activity [1] Group 2: New Listings and Performance - New stocks with fundraising of $100 million or more saw an average first-day price increase of 23.8%, with an average one-month increase of 30.7%, marking the best performance in nearly 20 years [5] - Notable transactions included 20 large deals exceeding $1 billion, including the largest placement in the global automotive sector and the second-largest convertible bond deal in the tech sector [5] Group 3: Investor Participation - The investor base in Hong Kong's primary and secondary markets has become increasingly diverse, including global institutional investors and retail investors from mainland China [9] - Institutional investors accounted for a significant portion of the top 20 most active cornerstone investors in Hong Kong's equity capital market [9] Group 4: Industry Diversity - Hong Kong maintained its status as a diversified fundraising center, ranking among the top globally in various industry fundraising scales [11] - In the industrial and new energy sectors, Hong Kong ranked first globally in new stock fundraising at $14.3 billion and second in equity capital market issuance at $24.7 billion [13] Group 5: Future Trends - The capital market in Hong Kong started strong in 2026, with equity capital market issuance reaching $15.8 billion by January 30, six times the amount from the same period in 2025 [16] - The artificial intelligence sector is expected to play a significant role in IPO activities, contributing to a vibrant ecosystem for innovative companies [16]

摩根大通发表研报指，信达生物与礼来达成战略合作，共同在全球范围开发聚焦于肿瘤和免疫学领域的 新型生物制剂。该行认为此次合作属正面惊喜，标志着信达生物迈向全球性生物制药公司历程中的又一 个重要里程碑，并突显其研发平台的实力。在电话会议上，信达生物管理层重申其长期愿景，主要受惠 于通用生物药和肿瘤药领域双引擎增长策略的支持。该行对信达生物在其商业及研发产品在线的执行 力，以及其强大的业务拓展能力持续印象深刻。该行重申信达生物是其所覆盖的中国生物科技公司中的 首选标的之一，予其"增持"评级，目标价为111港元。 ...

Core Viewpoint - The pharmaceutical industry is experiencing growth due to persistent human demand and unmet needs, alongside increased R&D investments by companies, marking the transition to an "innovation-driven" revenue era in China [1]. Group 1: Index Performance - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index rose by 2.1% [1]. - The Hang Seng Hong Kong Stock Connect Innovative Drug Index increased by 2.0% [1]. - The CSI Biotechnology Theme Index saw a rise of 0.6% [1]. - The CSI Innovative Drug Industry Index grew by 0.4% [1]. - The CSI 300 Pharmaceutical and Health Index experienced a slight increase of 0.2% [1]. Group 2: Index Composition - The index focuses on leading innovative drug companies in A-shares, comprising no more than 50 stocks involved in innovative drug R&D [5]. - The index tracks leading biotechnology companies in A-shares, including no more than 50 stocks related to gene diagnostics, biopharmaceuticals, and other human biotechnology [7]. - The index covers leading companies in the pharmaceutical and health industry within the CSI 300, including segments like chemical pharmaceuticals, medical services, and medical devices [9]. Group 3: Valuation Metrics - The rolling P/E ratio for the innovative drug index is 50.4 times, with a valuation increase of 72.3% since its inception [6]. - The rolling P/E ratio for the biotechnology index is 53.2 times, with a valuation increase of 58.7% since its inception [8]. - The rolling P/E ratio for the CSI 300 Pharmaceutical and Health Index is 29.9 times, with a valuation increase of 39.2% since its inception [10].

Group 1 - The recent Japanese general election results indicate that the ruling coalition of the Liberal Democratic Party (LDP) and the Japan Innovation Party has secured a majority, with the LDP winning 316 seats and the Japan Innovation Party winning 36 seats, ensuring short-term stability in economic policy [2] - Japan's GDP growth rate is projected to be approximately 1.1% for the year 2025, reflecting a continued low-growth trend, which suggests that the government may maintain a moderately expansionary fiscal policy to support economic growth in the short term [2][4] - The Bank of Japan is expected to gradually exit its ultra-loose monetary policy by 2025, but will face challenges in balancing economic stimulation and preventing excessive depreciation of the yen, as core inflation remains weak at around 1.8% [3] Group 2 - Japan is facing long-term structural challenges, including an aging population, declining labor force, and rising social security expenditures, which are constraining the potential growth rate of the economy [3][4] - The manufacturing sector is showing signs of weakness, with the PMI for December 2025 recorded at 49.8, indicating contraction, while Japan lags behind the US and China in emerging industries such as AI and biotechnology [3] - Although the LDP's continued governance provides short-term stability and potential policy benefits, it does not address the underlying structural issues that hinder long-term economic growth [4]

威灵顿投资管理：三大因素驱动全球投资者增配中国股票资产 中新社上海2月9日电 (记者 姜煜)全球规模最大的独立投资管理公司威灵顿投资管理9日发布机构观点 称，三大因素驱动全球投资者增配中国股票资产。 该机构分析，近年来，全球投资者对中国股票的投资兴趣持续增长，投资主体也从以往的传统新兴市场 基金，扩展至全球纯多头基金和对冲基金。这一变化的背后主要有三大驱动因素：首先，市场对中国企 业不断提升的竞争力和创新潜力给予更多认可，同时中国股票整体估值具有相对优势；其次，外部环境 趋于缓和，市场风险溢价相应下降；第三，中国国内政策与资本市场发展、企业盈利水平以及经济结构 转型之间的协同性持续增强，增强了投资环境的吸引力。 来源：中国新闻网 编辑：熊思怡 广告等商务合作，请点击这里 本文为转载内容，授权事宜请联系原著作权人 中新经纬版权所有，未经书面授权，任何单位及个人不得转载、摘编或以其它方式使用。 关注中新经纬微信公众号(微信搜索"中新经纬"或"jwview")，看更多精彩财经资讯。 威灵顿投资管理宏观策略师郁嘉言表示，当前全球主要发达市场的估值普遍处于历史高位，后续上行空 间相对有限。在此背景下，中国市场的强劲表现 ...

Core Viewpoint - The recent Japanese House of Representatives election resulted in a significant victory for the Liberal Democratic Party (LDP), securing 316 seats, which is over two-thirds of the total, indicating potential constitutional amendments in the long term, while short-term economic policies remain the priority [1][2]. Election Results - The LDP achieved 316 seats, up from 198, representing approximately 68% of the total 465 seats, marking the largest single-party representation since 1945 [1]. - The Komeito party, part of the ruling coalition, gained 36 seats, while the largest opposition party, the Constitutional Democratic Party, saw a significant drop to 49 seats from 167 [1]. - The National Democratic Party maintained its seat count at 28, and the Future Team party made a notable breakthrough with 11 seats [1]. Constitutional Amendment Possibility - The current political landscape allows for a potential constitutional amendment, as parties supporting such changes hold over two-thirds of the seats in both houses of parliament [2]. - However, the focus will likely remain on economic policies in the short term, as public concern centers around inflation and purchasing power [2]. Economic Policy Focus - The LDP's election manifesto emphasizes crisis management investments across various sectors, including technology, energy, and healthcare, aiming to enhance national resilience and competitiveness [2][3]. - Specific strategies include promoting Japan as a technology powerhouse, reducing dependency on specific countries, and ensuring supply chain security for critical resources [3]. Energy Security Measures - The manifesto outlines plans to restart nuclear power plants and maximize the use of renewable energy sources, aiming for a more diversified and self-sufficient energy structure [4]. - It also includes measures to regulate solar energy projects to balance development with local community and environmental needs [4]. Fiscal Responsibility - The LDP aims to achieve strong economic growth through bold investments while ensuring fiscal sustainability, with plans to reduce government debt as a percentage of GDP [4]. Market Impact - The election outcome is expected to lead to a significant rise in Japanese stocks, with the Nikkei index potentially surpassing 56,000 points [5]. - Japanese bond yields may rise in an orderly manner, with the LDP's victory suggesting a focus on responsible fiscal policies [6]. - The impact on U.S. Treasury yields is expected to be minimal, as Japan's holdings of U.S. debt are relatively small [7]. - There may be foreign exchange interventions if the yen depreciates excessively, with potential intervention levels around 158-160 yen per dollar [8]. - Global market sentiment may improve as a result of the election, reducing downward risks to capital prices [8]. Political Dynamics - Despite the LDP's strong position, concerns exist regarding the potential for overreach in policy implementation, drawing parallels to past political disappointments in Japan [9]. - Ongoing monitoring of cabinet approval ratings and financial market reactions will be crucial in shaping future policies [10].

作为我国经济高质量发展的两大核心增长极，长三角与粤港澳大湾区遥相呼应。高铁拉近了距离，如何 让协同发展更有"含金量"？省政协委员、江苏澳盛复合材料科技有限公司董事局主席许文前聚焦苏港科 创合作，为两大区域协同发展支招。他以澳盛科技为例：企业相关项目斩获江苏省科技进步奖一等奖， 正是苏港科创互补共赢的结果。 "香港是国际科创中心，在人工智能、生物科技等领域实力雄厚；江苏是制造业大省，产业全、市场 广，两地本是'黄金搭档'。"他也坦言，现实中，香港不少科研成果困在实验室，难以从"样品"变为"商 品"，苏港协同发展存在合作零散缺乏系统布局、人才对接不精准等症结。许文前建议，设立苏港制造 业创新转化基金，政企协同、市场化运作，重点支持香港科创项目中试和产业化；构建全链条支撑体 系，设立概念验证资金、共建创新平台，打通成果转化中间环节；完善配套政策，对落地项目给予奖 励，为香港科创人才提供落户、教育、医疗"一站式"服务。 □ 本报记者王梦然 "南京到香港的高铁通了，可以'早吃南京鸭血粉丝，晚品香港菠萝油'，未来长三角和大湾区如何更好 地协同发展？"近日，交汇点新闻客户端"我请代表委员捎句话"栏目中，网友的提问，道出了大 ...